Prognostic Biomarker of Fertility‐Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer
Cancer Science · 2026
DOI: 10.1111/cas.70240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Takuro Hirano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Biomarkers, Tumor, Fertility Preservation, Medroxyprogesterone Acetate. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In this study, we identified prognostic biomarkers that predict treatment outcome in patients receiving fertility‐preserving high‐dose medroxyprogesterone acetate (MPA) therapy through comprehensive multigene panel testing. A total of 38 patients (20 atypical endometrial hyperplasia and 18 stage IA G1 without myometrial invasion) who received first‐line MPA therapy were enrolled. Genomic DNA was extracted from formalin‐fixed paraffin‐embedded samples, and PleSSision‐Rapid multigene panel testing was performed. Of the 38 patients, 31 (82%) achieved complete response (CR), 2 (5%) had stable disease (SD), and 5 (13%) had progressive disease (PD) following initial treatment. The median duration to achieve tumor disappearance was 7 months (range: 4–14 months). Following initial treatment, 25 of 32 patients (78%) experienced recurrence, with a median recurrence‐free survival (RFS) of 21 months (range: 2–84 months). The most frequently observed actionable gene mutations were PTEN (68.4%), CTNNB1 (55.2%), and PIK3CA (33.3%). Patients harboring PTEN mutations in EMG1 required a significantly longer duration to achieve tumor disappearance ( p = 0.011). In addition, the presence of PIK3CA mutations in AEH was significantly associated with shorter RFS ( p = 0.048). Molecular classification identified 34 patients (89%) with no specific molecular profile (NSMP), 1 patient (3%) with POLE mutation, and 3 patients (8%) with deficient mismatch repair (d‐MMR). Most patients undergoing MPA therapy were classified as having NSMP. Genetic alterations, specifically mutations in PTEN and PIK3CA , were significantly associated with treatment outcomes, highlighting their potential as prognostic biomarkers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics & Gynecology, Keio University School of Medicine, Tokyo, Japan.
- Department of Obstetrics & Gynecology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.
- Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan.
- Surgical Pathology, Ito Hospital, Kanazawa, Japan.
- Department of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Narita, Japan.
- Akasaka Sannou Medical Center, Minato, Japan.
ORCID-Profile: Takuro Hirano, Kensuke Sakai, Takuma Yoshimura, Tatsuyuki Chiyoda, Kohei Nakamura, Eriko Aimono, Miho Kawaida, Hiroshi Nishihara, Nobuyuki Susumu, Daisuke Aoki, Wataru Yamagami
Zitieren
APA
Hirano, T., Sakai, K., Yoshimura, T., Chiyoda, T., Nakamura, K., Aimono, E., Kawaida, M., Nishihara, H., Susumu, N., Aoki, D., & Yamagami, W. (2026). Prognostic Biomarker of Fertility‐Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer. Cancer Science. https://doi.org/10.1111/cas.70240
Vancouver
Hirano T, Sakai K, Yoshimura T, Chiyoda T, Nakamura K, Aimono E, et al. Prognostic Biomarker of Fertility‐Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer. Cancer Science. 2026. doi:10.1111/cas.70240
BibTeX
@article{Hirano2026,
author = {Hirano, Takuro and Sakai, Kensuke and Yoshimura, Takuma and Chiyoda, Tatsuyuki and Nakamura, Kohei and Aimono, Eriko and Kawaida, Miho and Nishihara, Hiroshi and Susumu, Nobuyuki and Aoki, Daisuke and Yamagami, Wataru},
title = {Prognostic Biomarker of Fertility‐Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70240}
}
EUVIMED